Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
EIF3A	rs3740556	AA + AG	carboplatin	efficacy	no	No significant difference in median survival time (months) was seen between carriers of the A allele and GG homozygotes for those with small cell lung cancer. However, significant differences were seen when considering patients with non-small cell lung cancer.	Genotypes AA + AG are not associated with response to carboplatin and cisplatin in people with Carcinoma, Small Cell as compared to genotype GG.	23127338	982046831
EIF3A	rs3740556	AA + AG	carboplatin	efficacy	yes	Carriers of the A allele had increased median survival time (months) compared to GG homozygotes. However, no significant results were seen when considering patients with small cell lung cancer.	Genotypes AA + AG are associated with increased response to carboplatin and cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG.	23127338	982046834
EIF3A	rs3740556	AA + AG	carboplatin	efficacy	yes	Responders were defined as those with complete response or partial response (n=328); non-responders were defined as those with stable disease or progressive disease (n=443). Patients with the AG + AA genotypes had a decreased risk of platinum resistance (i.e. more likely to be a responder) as compared to GG homozygotes.	Genotypes AA + AG are associated with increased response to carboplatin and cisplatin in people with Lung Neoplasms as compared to genotype GG.	23127338	982046815